Project Grant R01AG098153
- Federal Project Grant Award Summary The University of North Carolina at Chapel Hill received a $1,221,276 Project Grant award from the National Institute on Aging under the Aging Research program (CFDA 93.866) to develop and apply Single-Cell Massively Parallel Reporter Assays (SCMPRA), a novel genomic platform for investigating Alzheimer's disease-associated cis-regulatory elements (CREs). The research addresses a critical gap in understanding the molecular mechanisms of Alzheimer's disease...
- Federal Grant Award Summary The University of North Carolina at Chapel Hill received a $426,674 Project Grant from the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866) for the period September 1, 2025, through August 31, 2027. The research project, titled "Implications of Long-Range Mossy Cell Signaling and Connectivity in Alzheimer's Disease," investigates synaptic and circuit-level mechanisms underlying cognitive and affective impairments in...
- Federal Grant Award Summary The National Institute on Aging (NIA) awarded a Project Grant of $142,607.00 to the University of North Carolina at Chapel Hill under the Aging Research program (CFDA 93.866), effective September 1, 2025, with a completion date of May 31, 2030. Dr. Tengfei Li, a Research Assistant Professor in the Department of Radiology, will lead development of advanced statistical and machine learning methodologies to establish life-span brain structural reference standards for...
- Federal Project Grant Award Summary Duke University's Office of Research Administration was awarded $509,413 by the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866) on September 15, 2025, for a project period extending through May 31, 2030. The award supports scientific research investigating epitranscriptomic regulation of microglia in Alzheimer's disease (AD), specifically examining how m6A (N6-methyladenosine) modifications of messenger RNA control microglial...
- Federal Grant Award Summary The University of South Florida received a $3.3 million Project Grant from the National Institute on Aging under the Aging Research program (CFDA 93.866) effective September 1, 2025 through August 31, 2029. This award supports the development of novel peptidomimetic biomaterials designed to inhibit amyloid-beta (Aβ42) aggregation as a therapeutic intervention for Alzheimer's disease. The primary deliverables include the rational design and synthesis of structurally...
- Federal Grant Award Summary Fox Chase Chemical Diversity Center Inc. received a $1.07 million Project Grant from the National Institute on Aging under the Aging Research program (CFDA 93.866), effective March 1, 2026 through November 30, 2030. The award supports AI-driven discovery of in vivo chemical probes targeting understudied proteins relevant to Alzheimer's disease and related dementias (ADRD). The project will systematically evaluate 15 proteins annually from the 900-protein portfolio...
- Federal Grant Award Summary Purdue University received a $1,293,752 Project Grant from the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866), awarded February 15, 2026, with completion targeted for January 31, 2031. The award funds development of an integrated artificial intelligence (AI) platform designed to advance peptide drug design for Alzheimer's disease (AD) and related dementias (ADRD). The project delivers generative AI models for sequence- and...
- Federal Project Grant Award Summary The University of North Carolina at Chapel Hill received a $696,824 Project Grant award, effective August 11, 2025, through June 30, 2029, from the National Institute of Biomedical Imaging and Bioengineering under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286). The research initiative focuses on developing robust and interpretable multi-modal artificial intelligence and machine learning (AI/ML)...
- Federal Project Grant Award Summary The National Institute on Aging (NIA) awarded Indiana University a $1.23 million Project Grant under the Aging Research program (CFDA 93.866) to develop artificial intelligence-driven virtual screening pipelines for identifying brain-penetrant drug candidates targeting Alzheimer's disease and related dementias (AD/ADRD). The five-year project, running from February 1, 2026, through January 31, 2031, will deliver computational tools and datasets designed to...
- Federal Project Grant Award Summary Duke University's Office of Research Administration received a $493,972 Project Grant from the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866), effective January 1, 2026 through December 31, 2030. This award funds research on cell type-specific epitranscriptomic regulation in the brain during aging and Alzheimer's disease (AD). The project investigates how adenosine methylation (M6A), the most abundant internal messenger RNA...
The University of North Carolina at Chapel Hill received a $1.25 million Project Grant from the National Institute on Aging under the Aging Research program (CFDA 93.866) to develop an integrated artificial intelligence (AI)-driven computational and experimental workflow for accelerating small-molecule drug discovery targeting Alzheimer's disease. The award, effective February 15, 2026 through January 31, 2031, supports research aimed at identifying chemical probes and modulators for proteins (PLC2, MOESIN, GEF-H1, and SHIP1) that regulate microglial phagocytosis and influence Alzheimer's disease pathology. The project deliverables include: (1) development and application of AI-driven methods to design DNA-encoded libraries targeting seven binding sites across the four proteins; (2) implementation of an integrated AI-computational and experimental pipeline for hit discovery and validation; and (3) AI-assisted optimization of promising lead compounds to enhance efficacy in cellular models. This research addresses a critical gap in current drug discovery methodologies by combining sophisticated computational approaches with rigorous experimental validation, building upon advances previously made through the National Institute on Aging-supported Accelerating Medicines Partnership in Alzheimer's Disease initiative. By integrating AI-driven predictions with systematic experimental pipeline workflows, the project aims to overcome traditional screening limitations and accelerate the translation of computational results into viable therapeutic candidates for treating Alzheimer's disease.Federal Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $1.3m | 2/13/26 |